Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 36, 2005, Pages 5685-5687

  Enjoji, Munechika ^a   Morizono, Shusuke ^a   Kotoh, Kazuhiro ^a   Kohjima, Motoyuki ^a   Miyagi, Yuzuru ^a   Yoshimoto, Tsuyoshi ^a   Nakamuta, Makoto ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Chemotherapy; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATIC ARTERY; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; ONCOLOGICAL PARAMETERS; PREDICTION; THROMBOCYTOPENIA; TUMOR VOLUME;

EID: 28044457714     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i36.5685     Document Type: Article

References (15)

1. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1764-1765
2. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M. Combined intra-arterial 5-fluorouracil and subcutaneous IFN-alfa therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-442
3. Moriyama M, Hoshida Y, Kato N, Otsuka M, Yoshida H, Kawabe T, Omata M. Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-α combination chemotherapy. Int J Oncol 2004; 25: 1279-1287
4. Schwartz EL, Baptiste N, Wadler S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995; 270: 19073-19077
5. Dou J, Iwashita Y, Sasaki A, Kai S, Hirano S, Ohta M, Kitano S. Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression. Liver Int 2005; 25: 148-152
6. Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-α /5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 2004; 10: 7884-7895
7. Eguchi H, Nagano H, Yamamoto H, Miyamoto A, Kondo M, Dono K, Nakamori S, Umeshita K, Sakon M, Monden M. Augmentation of anti-tumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000; 6: 2881-2890
8. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. Integration of interferon alpha/beta signaling to p53 response in tumor suppression and antiviral defense. Nature 2003; 424: 516-523
9. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002; 71: 565-581
10. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Ann Rev Biochem 1998; 67: 227-264
11. Grifith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor related cytokine, TRAIL. J Exp Med 1999; 189: 1343-1354
12. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451-1460
13. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, Yagita H, Okumura K, Tanaka N, Taniguchi T, Ogasawara K. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001; 31: 3138-3146
14. Patt YZ, Yoffe B, Charnsangavej C, Pazdur R, Fischer H, Cleary K, Roh M, Smith R, Noonan CA, Levin B. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 1993; 72: 2574-2582
15. Kurokawa Y, Matoba R, Nagano H, Sakon M, Takemasa I, Nakamori S, Dono K, Umeshita K, Ueno N, Ishii S, Kato K, Monden M. Molecular prediction of response to 5-fluorouracil and interferon-α combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 2004; 10: 6029-6038